Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113118
Chunk: 7

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 7
---

contained herein until after we distribute this Quarterly Report, whether as a result of any new information, future events or otherwise.

In addition, statements that
“we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon
information available to us as of the date of this Quarterly Report, and while we believe such information forms a reasonable basis for
such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted
an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and
you are cautioned not to unduly rely upon these statements.

This Quarterly Report includes
trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, trademarks and tradenames
referred to in this Quarterly Report appear without the ® and ™ symbols, but those references are not intended to indicate,
in any way, that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert
its rights, to these trademarks and tradenames.

Unless the context otherwise
requires, the “Company,” for periods prior to the Closing, refers to CERo Therapeutics, Inc. (“Predecessor”),
and for the periods after the Closing, refers to CERo Therapeutics Holdings, Inc. (“Successor”).

<div align='center'>iv

SELECTED DEFINITIONS</div>

As used in this Quarterly
Report, unless otherwise noted or the context otherwise requires, references to the following capitalized terms have the meanings set
forth below:

“Board of directors”
refers to the board of directors of CERo.

“Business Combination”
or “Merger” refers to the transactions contemplated by the Business Combination Agreement, including the merger between
Merger Sub and Legacy CERo.

“Business Combination Agreement”
refers to the Business Combination Agreement, dated as of June 4, 2023, as amended by Amendment No. 1, dated February 5, 2024 and Amendment
No. 2, dated February 13, 2024, by and between PBAX, Merger Sub and Legacy CERo.

“Bylaws” refers
to the Amended and Restated Bylaws of CERo.

“Charter” refers
to CERo’s Second Amended and Restated Certificate of Incorporation, as filed with the Secretary of the State